Business Description
Kangmei Pharmaceutical Co Ltd
NAICS : 325411
ISIN : CNE0000017M1
Share Class Description:
SHSE:600518: Class ACompare
Compare
Traded in other countries / regions
600518.China IPO Date
2001-03-19Description
Kangmei Pharmaceutical Co Ltd is a pharmaceutical company engaged in the manufacturing, research and marketing of herbal medicine and chemical raw materials.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.14 | |||||
| Equity-to-Asset | 0.49 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | 1.53 | |||||
| Interest Coverage | 0.8 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 0.33 | |||||
| Beneish M-Score | -2.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.6 | |||||
| 3-Year EPS without NRI Growth Rate | 79.1 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.55 | |||||
| 9-Day RSI | 53.74 | |||||
| 14-Day RSI | 50.89 | |||||
| 6-1 Month Momentum % | 14.44 | |||||
| 12-1 Month Momentum % | 2.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.46 | |||||
| Quick Ratio | 0.89 | |||||
| Cash Ratio | 0.23 | |||||
| Days Inventory | 245.04 | |||||
| Days Sales Outstanding | 142.92 | |||||
| Days Payable | 205.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -40.7 | |||||
| Shareholder Yield % | -0.05 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 17.07 | |||||
| Operating Margin % | 0.93 | |||||
| Net Margin % | 2.1 | |||||
| FCF Margin % | -8.56 | |||||
| ROE % | 1.48 | |||||
| ROA % | 0.7 | |||||
| ROIC % | 0.49 | |||||
| ROC (Joel Greenblatt) % | 4.04 | |||||
| ROCE % | 1.74 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 290 | |||||
| PE Ratio without NRI | 1015 | |||||
| PS Ratio | 5.14 | |||||
| PB Ratio | 3.98 | |||||
| Price-to-Tangible-Book | 4.32 | |||||
| EV-to-EBIT | 161.7 | |||||
| EV-to-EBITDA | 161.7 | |||||
| EV-to-Revenue | 5.52 | |||||
| EV-to-FCF | -64.53 | |||||
| Price-to-Median-PS-Value | 1.3 | |||||
| Price-to-Graham-Number | 14.5 | |||||
| Earnings Yield (Greenblatt) % | 0.62 | |||||
| FCF Yield % | -1.48 | |||||
| Forward Rate of Return (Yacktman) % | -32.94 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers